NasdaqGM:CDNABiotechs
Does ACROBAT AlloHeme Validation Broaden CareDx’s (CDNA) Transplant+ Thesis Into Hematology-Oncology?
CareDx, Inc. recently reported pivotal clinical validation results from its ACROBAT study for AlloHeme, an AI- and NGS-based blood test that predicts relapse in acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic cell transplant, showing high sensitivity, specificity, and earlier relapse detection than traditional methods.
This successful validation of AlloHeme marks a meaningful broadening of CareDx’s Transplant+ platform beyond solid organ transplantation...